Effect of cilostazol on arterial stiffness and vascular adhesion molecules in type 2 diabetic patients with metabolic syndrome: A randomised, double-blind, placebo-controlled, crossover trial

Diabetology and Metabolic Syndrome

Volumn 5, Issue 1, 2013, Pages

  Kim, Nam Hoon ^a   Kim, Hee Young ^a   An, Hyonggin ^b   Seo, Ji A ^a   Kim, Nan Hee ^a   Choi, Kyung Mook ^a   Baik, Sei Hyun ^a   Choi, Dong Seop ^a   Kim, Sin Gon ^a  

^a Korea University College of Medicine   (South Korea)

^b Korea University College of Medicine   (South Korea)

Author keywords

Arterial stiffness; Cilostazol; Metabolic syndrome; Phosphodiesterase inhibitor; Type 2 diabetes; Vascular adhesion molecules

Indexed keywords

ADIPONECTIN; C REACTIVE PROTEIN; CILOSTAZOL; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ANKLE; ARTERIAL STIFFNESS; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC PATIENT; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ENDOTHELIAL DYSFUNCTION; FEMALE; HUMAN; MALE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PULSE WAVE; VASCULITIS;

EID: 84881296254     PISSN: None     EISSN: 17585996     Source Type: Journal    
DOI: 10.1186/1758-5996-5-41     Document Type: Article

References (38)

1. Insulin resistance and chronic cardiovascular inflammatory syndrome. Fernandez-Real JM, Ricart W, Endocr Rev 2003 24 3 278 301 12788800 (Pubitemid 36724371)
2. Cytokine and cytokine-like inflammation markers, endothelial dysfunction, and imbalanced coagulation in development of diabetes and its complications. Goldberg RB, J Clin Endocrinol Metab 2009 94 9 3171 3182 10.1210/jc.2008-2534 19509100
3. High-sensitivity C-reactive protein and coronary heart disease mortality in patients with type 2 diabetes: a 7-year follow-up study. Soinio M, Marniemi J, Laakso M, Lehto S, Ronnemaa T, Diabetes Care 2006 29 2 329 333 10.2337/diacare.29.02.06.dc05-1700 16443882 (Pubitemid 44106513)
4. Endothelial dysfunction and low-grade inflammation explain much of the excess cardiovascular mortality in individuals with type 2 diabetes: the Hoorn study. de Jager J, Dekker JM, Kooy A, Kostense PJ, Nijpels G, Heine RJ, Bouter LM, Stehouwer CD, Arterioscler Thromb Vasc Biol 2006 26 5 1086 1093 10.1161/01.ATV.0000215951.36219.a4 16514084 (Pubitemid 43732116)
5. Elevated C-reactive protein associates with early-stage carotid atherosclerosis in young subjects with type 1 diabetes. Hayaishi-Okano R, Yamasaki Y, Katakami N, Ohtoshi K, Gorogawa S, Kuroda A, Matsuhisa M, Kosugi K, Nishikawa N, Kajimoto Y, Hori M, Diabetes Care 2002 25 8 1432 1438 10.2337/diacare.25.8.1432 12145246 (Pubitemid 41071157)
6. Association between IL-6 and the extent of coronary atherosclerosis in the veterans affairs diabetes trial (VADT). Saremi A, Anderson RJ, Luo P, Moritz TE, Schwenke DC, Allison M, Reaven PD, Atherosclerosis 2009 203 2 610 614 10.1016/j.atherosclerosis.2008.07.031 18804762
7. Noninvasive measures of cardiovascular changes in diabetes mellitus. Wadwa RP, Curr Opin Endocrinol Diabetes Obes 2007 14 4 263 268 10.1097/MED.0b013e32825a674d 17940450 (Pubitemid 47067109)
8. Aortic pulse-wave velocity and its relationship to mortality in diabetes and glucose intolerance: an integrated index of vascular function? Cruickshank K, Riste L, Anderson SG, Wright JS, Dunn G, Gosling RG, Circulation 2002 106 16 2085 2090 10.1161/01.CIR.0000033824.02722.F7 12379578 (Pubitemid 35192814)
9. Cilostazol as a unique antithrombotic agent. Kambayashi J, Liu Y, Sun B, Shakur Y, Yoshitake M, Czerwiec F, Curr Pharm Des 2003 9 28 2289 2302 10.2174/1381612033453910 14529391 (Pubitemid 37236353)
10. Cilostazol reduces atherosclerosis by inhibition of superoxide and tumor necrosis factor-alpha formation in low-density lipoprotein receptor-null mice fed high cholesterol. Lee JH, Oh GT, Park SY, Choi JH, Park JG, Kim CD, Lee WS, Rhim BY, Shin YW, Hong KW, J Pharmacol Exp Ther 2005 313 2 502 509 15734902 (Pubitemid 40604148)
11. Cilostazol, a selective type III phosphodiesterase inhibitor, decreases triglyceride and increases HDL cholesterol levels by increasing lipoprotein lipase activity in rats. Tani T, Uehara K, Sudo T, Marukawa K, Yasuda Y, Kimura Y, Atherosclerosis 2000 152 2 299 305 10.1016/S0021-9150(99)00480-3 10998457
12. The phosphodiesterase inhibitor cilostazol induces regression of carotid atherosclerosis in subjects with type 2 diabetes mellitus: principal results of the Diabetic Atherosclerosis Prevention by Cilostazol (DAPC) study: a randomized trial. Katakami N, Kim YS, Kawamori R, Yamasaki Y, Circulation 2010 121 23 2584 2591 10.1161/CIRCULATIONAHA.109.892414 20516379
13. Decrease in carotid intima media thickness after 1 year of cilostazol treatment in patients with type 2 diabetes mellitus. Ahn CW, Lee HC, Park SW, Song YD, Huh KB, Oh SJ, Kim YS, Choi YK, Kim JM, Lee TH, Diabetes Res Clin Pract 2001 52 1 45 53 10.1016/S0168-8227(00)00235-7 11182215 (Pubitemid 32143687)
14. Effect of cilostazol treatment on adiponectin and soluble CD40 ligand levels in diabetic patients with peripheral arterial occlusion disease. Hsieh CJ, Wang PW, Circ J 2009 73 5 948 954 10.1253/circj.CJ-08-0905 19282610
15. The vascular and biochemical effects of cilostazol in diabetic patients with peripheral arterial disease. O'Donnell ME, Badger SA, Sharif MA, Makar RR, Young IS, Lee B, Soong CV, Vasc Endovascular Surg 2009 43 2 132 143 10.1177/1538574408328586 19131370
16. Follow-up report on the diagnosis of diabetes mellitus. Genuth S, Alberti KG, Bennett P, Buse J, Defronzo R, Kahn R, Kitzmiller J, Knowler WC, Lebovitz H, Lernmark A, et al. Diabetes Care 2003 26 11 3160 3167 14578255 (Pubitemid 37339514)
17. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 2001 285 19 2486 2497 10.1001/jama.285.19.2486 11368702
18. Effect of pioglitazone on carotid intima-media thickness and arterial stiffness in type 2 diabetic nephropathy patients. Nakamura T, Matsuda T, Kawagoe Y, Ogawa H, Takahashi Y, Sekizuka K, Koide H, Metabolism 2004 53 10 1382 1386 10.1016/j.metabol.2004.05.013 15375799 (Pubitemid 39222104)
19. Practical efficacy of telmisartan for decreasing morning home blood pressure and pulse wave velocity in patients with mild-to-moderate hypertension. Uchida H, Nakamura Y, Kaihara M, Sugimoto T, Norii H, Sasaki M, Sato H, Makino H, Hypertens Res 2004 27 8 545 550 10.1291/hypres.27.545 15492473 (Pubitemid 39335071)
20. Comparison between carotid-femoral and brachial-ankle pulse wave velocity as measures of arterial stiffness. Tanaka H, Munakata M, Kawano Y, Ohishi M, Shoji T, Sugawara J, Tomiyama H, Yamashina A, Yasuda H, Sawayama T, Ozawa T, J Hypertens 2009 27 10 2022 2027 10.1097/HJH.0b013e32832e94e7 19550355
21. Brachial-ankle pulse wave velocity as an index of central arterial stiffness. Tsuchikura S, Shoji T, Kimoto E, Shinohara K, Hatsuda S, Koyama H, Emoto M, Nishizawa Y, J Atheroscler Thromb 2010 17 6 658 665 10.5551/jat.3616 20467192
22. Brachial-ankle pulse wave velocity predicts increase in blood pressure and onset of hypertension. Takase H, Dohi Y, Toriyama T, Okado T, Tanaka S, Sonoda H, Sato K, Kimura G, Am J Hypertens 2011 24 6 667 673 10.1038/ajh.2011.19 21331056
23. Arterial stiffness is strongly associated with insulin resistance in Chinese-a population-based study (Taichung Community Health Study, TCHS). Ho CT, Lin CC, Hsu HS, Liu CS, Davidson LE, Li TC, Li CI, Lin WY, J Atheroscler Thromb 2011 18 2 122 130 10.5551/jat.5686 21048381
24. Arterial stiffness measured as pulse wave velocity is highly correlated with coronary atherosclerosis in asymptomatic patients. Liu CS, Li CI, Shih CM, Lin WY, Lin CH, Lai SW, Li TC, Lin CC, J Atheroscler Thromb 2011 18 8 652 658 10.5551/jat.7021 21467807
25. Antiplatelet therapy using cilostazol, a specific PDE3 inhibitor. Ikeda Y, Thromb Haemost 1999 82 2 435 438 10605734
26. Effect of cilostazol, a phosphodiesterase inhibitor, on carotid IMT in Japanese type 2 diabetic patients. Mitsuhashi N, Tanaka Y, Kubo S, Ogawa S, Hayashi C, Uchino H, Shimizu T, Watada H, Kawasumi M, Onuma T, Kawamori R, Endocr J 2004 51 16 545 550 15644572 (Pubitemid 40209021)
27. Hemodynamic effect of cilostazol on increasing peripheral blood flow in arteriosclerosis obliterans. Yasuda K, Sakuma M, Tanabe T, Arzneimittelforschung 1985 35 7A 1198 1200 4074434 (Pubitemid 15030837)
28. [Effect of long-term cilostazol administration on coronary flow velocity and coronary flow reserve]. Tanaka T, Muneyuki T, Oka Y, Sada T, Kira Y, J Cardiol 1999 34 4 183 188 10553534 (Pubitemid 29510333)
29. Inhibition of lipopolysaccharide-induced apoptosis by cilostazol in human umbilical vein endothelial cells. Kim KY, Shin HK, Choi JM, Hong KW, J Pharmacol Exp Ther 2002 300 2 709 715 10.1124/jpet.300.2.709 11805237 (Pubitemid 34106268)
30. Cilostazol represses vascular cell adhesion molecule-1 gene transcription via inhibiting NF-kappaB binding to its recognition sequence. Otsuki M, Saito H, Xu X, Sumitani S, Kouhara H, Kurabayashi M, Kasayama S, Atherosclerosis 2001 158 1 121 128 10.1016/S0021-9150(01)00431-2 11500182 (Pubitemid 32735475)
31. Cilostazol inhibits high glucose-mediated endothelial-neutrophil adhesion by decreasing adhesion molecule expression via NO production. Omi H, Okayama N, Shimizu M, Fukutomi T, Nakamura A, Imaeda K, Okouchi M, Itoh M, Microvasc Res 2004 68 2 119 125 10.1016/j.mvr.2004.05.002 15313121 (Pubitemid 39093885)
32. A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study. Angiolillo DJ, Capranzano P, Goto S, Aslam M, Desai B, Charlton RK, Suzuki Y, Box LC, Shoemaker SB, Zenni MM, et al. Eur Heart J 2008 29 18 2202 2211 10.1093/eurheartj/ehn287 18567918
33. VCAM-1 on activated endothelium interacts with the leukocyte integrin VLA-4 at a site distinct from the VLA-4/fibronectin binding site. Elices MJ, Osborn L, Takada Y, Crouse C, Luhowskyj S, Hemler ME, Lobb RR, Cell 1990 60 4 577 584 10.1016/0092-8674(90)90661-W 1689216 (Pubitemid 20083814)
34. Expression of intercellular adhesion molecule-1 in atherosclerotic plaques. Poston RN, Haskard DO, Coucher JR, Gall NP, Johnson-Tidey RR, Am J Pathol 1992 140 3 665 673 1372160
35. Circulating adhesion molecules levels in type 2 diabetes mellitus and hypertension. Boulbou MS, Koukoulis GN, Makri ED, Petinaki EA, Gourgoulianis KI, Germenis AE, Int J Cardiol 2005 98 1 39 44 10.1016/j.ijcard.2003.07.037 15676164 (Pubitemid 40169850)
36. Alterations in cell adhesion molecules and other biomarkers of cardiovascular disease in patients with metabolic syndrome. Gomez Rosso L, Benitez MB, Fornari MC, Berardi V, Lynch S, Schreier L, Wikinski R, Cuniberti L, Brites F, Atherosclerosis 2008 199 2 415 423 10.1016/j.atherosclerosis.2007.11. 007 18096167
37. Circulating vascular cell adhesion molecule-1 correlates with the extent of human atherosclerosis in contrast to circulating intercellular adhesion molecule-1, E-selectin, P-selectin, and thrombomodulin. Peter K, Nawroth P, Conradt C, Nordt T, Weiss T, Boehme M, Wunsch A, Allenberg J, Kubler W, Bode C, Arterioscler Thromb Vasc Biol 1997 17 3 505 512 10.1161/01.ATV.17.3.505 9102169 (Pubitemid 27133140)
38. Reduction of inflammatory cytokine concentrations and improvement of endothelial functions in obese women after weight loss over one year. Ziccardi P, Nappo F, Giugliano G, Esposito K, Marfella R, Cioffi M, D'Andrea F, Molinari AM, Giugliano D, Circulation 2002 105 7 804 809 10.1161/hc0702.104279 11854119 (Pubitemid 34174919)